Oncology Brothers: Practice-Changing Cancer Discussions

Trastuzumab deruxtecan (T-DXd) + Pertuzumab FDA Approval in Adv HER2 Breast Cancer: DESTINY-Breast09

In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approval of T-DXd (trastuzumab deruxtecan) plus Pertuzumab for the treatment of HER2-positive metastatic breast cancer. Joined by Dr. Sara Tolaney, the lead author of the DESTINY-Breast 09 study, where we discussed the findings that show a significant improvement in progression-free survival (PFS) from 26.9 months to 40.7 months, with a hazard ratio of 0.56.
Key topics included:• The design and findings of the DESTINY-Breast09 trial• Comparison with traditional treatment regimen THP (trastuzumab, pertuzumab, and taxane)• The implications of these findings for clinical practice• The role of maintenance therapy and the potential for personalized treatment strategies• Common side effects associated with T-DXd and pertuzumab, including ILD (Interstitial Lung Disease)
Join us as we explore the future of HER2-positive breast cancer treatment and the exciting developments that are changing the landscape for patients.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
 Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights!
#HER2positiveBreastCancer, #TrastuzumabDeruxtecan, #DestinyBreast09, #MetastaticBreastCancer, #OncologyBrothers

Navigating Acute Myeloid Leukemia Treatment: Therapy-Related & De Novo AML with Dr. Naval Daver

In this episode of the Oncology Brothers podcast, we discussed two challenging cases focused on Acute Myeloid Leukemia (AML). We welcomed Dr. Naval Daver, a leading expert from MD Anderson Cancer Center, to discuss: therapy-related AML and de novo AML where induction chemotherapy is not an option.
Episode Highlights:• Overview of therapy-related AML and its increasing prevalence due to advancements in solid tumor treatments.• In-depth discussion on the prognosis and treatment options for patients with complex cytogenetics.• Comparison of induction treatments: CPX-351 vs. the traditional 7 + 3 regimen, including survival rates and side effects.• Insights into the use of hypomethylating agents combined with venetoclax for older patients with AML, particularly those with NPM1 mutations.• Practical considerations for administering these treatments in both inpatient and outpatient settings.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of AML management.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to subscribe for more discussions on treatment algorithms, conference highlights, and the latest FDA approvals!
#AcuteMyeloidLeukemia, #TherapyRelatedAML, #DeNovoAML, #TransplantIneligible, #OncologyBrothers

Head & Neck Cancers Treatment Landscape & Algorithm – Dr. Fangdi Sun

In this episode of the Oncology Brothers podcast, we dived into the current treatment landscape for head and neck cancer. We welcomed Dr. Fangdi Sun, a head and neck medical oncologist from Stanford University, to discuss key topics including:• The importance of initial workup and the role of biomarkers, including HPV and EBV testing.• Treatment paradigm for early-stage and locally advanced head and neck cancers, focusing on the differences between HPV-positive and HPV-negative disease.• The evolving role of immunotherapy and the new perioperative approaches in treatment.• Insights into managing metastatic disease, including the use of PD-L1 scores and systemic therapy options.• The significance of multidisciplinary collaboration in optimizing patient care.
Whether you're a healthcare professional or simply interested in oncology, this episode provides valuable insights into the complexities of head and neck cancer treatment. Don't miss out on this informative discussion!
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Subscribe to our channel for more episodes as we continue to bridge the gap in oncology!#HeadAndNeckCancer, #HPV, #Immunotherapy, #MultidisciplinaryCare, #OncologyBrothers

FDA Approval of Daratumumab in High Risk Smoldering Myeloma: AQUILA by Dr. Vincent Rajkumar

In this episode of the Oncology Brothers podcast, we dived into the recent FDA approval of daratumumab for high-risk smoldering myeloma, based on the groundbreaking AQUILA study. We were joined by Dr. Vincent Rajkumar, a world-renowned myeloma specialist, who provided valuable insights into the complexities of smoldering myeloma, its risk stratification, and the implications of early intervention.
Key topics discussed included:• The definition and classification of smoldering myeloma• The design and findings of the AQUILA trial• The significance of time to progression and overall survival in treatment• The risk-benefit analysis of daratumumab therapy, including potential side effects• Future directions in myeloma treatment and ongoing research
Join us for an informative discussion as we bridge the gap between academic research and community practice, helping healthcare professionals and patients navigate the evolving landscape of myeloma treatment.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, conference highlights, and FDA approvals!

ASH 2025 Multiple Myeloma Highlights – AQUILA, COBRA, TecLILLE, MajesTEC-3: Dr. Ben Derman

Feeling overwhelmed by the rapid pace of change in multiple myeloma? ASH 2025 delivered potentially practice-changing data that could redefine second-line therapy and beyond.
In this episode, we sat down with myeloma specialist Dr. Ben Derman from the University of Chicago to dissect the most critical studies. We moved from the controversial treatment of high-risk smoldering myeloma to head-to-head comparisons in newly diagnosed disease, and finally, to the groundbreaking bispecific antibody data that is set to revolutionize care at first relapse.
Key topics covered in this episode:● AQUILA update: Daratumumab in high-risk smoldering myeloma, and the ongoing clinical dilemma● COBRA: Is KRD superior to VRD in newly diagnosed multiple myeloma? Unpacking the MRD and PFS data.● TecLILLE: A first look at Teclistamab + Daratumumab in frontline, transplant-ineligible patients.● MajesTEC-3: PFS and OS data for Teclistamab + Daratumumab in first relapse, and its impending FDA approval.
Tune in for this expert breakdown to navigate the new myeloma landscape with confidence.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Subscribe for more deep dives into treatment algorithms and major conference highlights!
#OncologyBrothers #ASH2025 #MultipleMyeloma #Myeloma #SmolderingMyeloma #BispecificAntibody #Teclistamab #Daratumumab #CART

GI ASCO 2026 Highlights MATTERHORN, HERIZON-GEA-01, BREAKWATER, COMMIT – Dr. Rachna Shroff

We’re kicking off 2026 with practice-changing data fresh from GI ASCO 2026. In this episode, we were joined once again by Dr. Rachna Shroff from the University of Arizona Cancer Center to break down the four most pivotal studies in upper GI and colorectal cancers presented at the GI ASCO 2026.
We dived into the latest updates that will directly impact your clinical decisions, from new standards in perioperative therapy to revolutionary front-line regimens for metastatic disease.
Key topics covered in this episode:● MATTERHORN update: Surgical outcomes & FLOT modifications with Durvalumab in resectable gastric/GEJ cancer● HERIZON-GEA-01: Zanidatamab + chemo + Tislelizumab the new frontline standard for HER2+ gastric cancer● BREAKWATER: Confirming Encorafenib + Cetuximab + chemo (FOLFOX or FOLFIRI) for BRAF V600E mCRC● COMMIT: Chemo + Atezolizumab vs. Atezolizumab alone in MSI-H/dMMR metastatic colorectal cancer
Tune in for this dense, insightful recap and stay ahead of the curve.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don’t forget to subscribe for more expert analysis on treatment algorithms and major conference highlights!#OncologyBrothers #GI26 #GastricCancer #ColorectalCancer #HER2 #BRAF #MSI #OncologyPodcast

ASH 2025 Lymphoma Highlights - EPCORE FL-1, CLL-17, BRUIN CLL-313, SWOG-1826: Dr. Julie Vose

In this episode of the Oncology Brothers podcast, we were joined by Dr. Julie Vose, a leading expert in lymphoma from the University of Nebraska Medical Center. Together, we delved into the key abstracts presented at ASH 2025, focusing on significant studies in lymphoma and chronic lymphocytic leukemia (CLL).Episode Highlights:● EPCORE FL-1: the approval of Epcoritamab in combination with Rituximab and lenalidomide for relapsed refractory follicular lymphoma● CLL-17: comparison between continuous BTK inhibitors and fixed-duration venetoclax with obinutuzumab● BRUIN CLL-313: insights into the non-covalent BTK inhibitor, pirtobrutinib, and its effectiveness in the frontline setting compared to traditional treatments● S1826: a three-year update on the use of Nivolumab-AVD versus BV-AVD in advanced-stage Hodgkin's lymphoma, showcasing improved PFS and better tolerability
Join us as we unpack these practice-changing studies and discuss their implications for community oncologists.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to subscribe for more insights and highlights from oncology conferences!#ASH25 #Oncology #Hematology #Lymphoma #CLL #CancerResearch

ASH 2025 Leukemia Highlights PARADIGM, KOMET-007, ASC4FIRST, ASC2ESCALATE - Dr. Jorge Cortes

In this episode of the Oncology Brothers podcast, we dived into the key highlights from ASH 2025, focusing on advancements in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).
We welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss key studies from the leukemia space, including the PARADIGM trial comparing Azacitidine plus Venetoclax to traditional 7 + 3 induction chemotherapy for fit patients with newly diagnosed AML. We explore the implications of these findings, the potential for hypomethylating agents in treatment regimens, and the evolving landscape of CML therapies, including the promising results from the ASK4FIRST/ASK2ESCALATE featuring Asciminib.Key topics covered in this episode:● The PARADIGM trial and its impact on AML treatment strategies● Real-world evidence on shortened venetoclax dosing● The role of menin inhibitors in combination therapies● Patient-reported outcomes and quality of life with asciminib in CMLTune in for an insightful discussion on the future of leukemia treatment and the importance of patient-centered care. 
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to subscribe for more updates on treatment algorithms, recent approvals, and conference highlights!
#OncologyBrothers #ASH2025 #ASH25 #AML #CML #Leukemia #Hematology

HER2+ SABCS 2025 Highlights DESTINY Breast-05/Breast-11, HER2CLIMB-05, PATINA: Dr. Harold Burstein

Join us as we dive into the latest advancements in HER2-positive breast cancer from SABCS 2025. In this episode, we discussed key studies including DESTINY Breast-11 and DESTINY Breast-05, highlighting their implications for neoadjuvant and adjuvant treatments. We also explored the HER2CLIMB-05 trial and the recent approval of TDXD with pertuzumab in frontline settings for metastatic HER2-positive disease.
Special guest Dr. Harold Burstein from Dana-Farber Cancer Institute shared his insights on the evolving landscape of HER2-positive breast cancer treatment, including the importance of patient selection and the management of side effects like interstitial lung disease (ILD).
Tune in for a comprehensive recap of the latest data, treatment algorithms, and how these advancements are changing the lives of patients with HER2-positive breast cancer.
Don't forget to like, subscribe, and check out our other episodes for more updates on treatment options and conference highlights!
Topics Covered:• DESTINY Breast-11 and its impact on neoadjuvant therapy• Insights from DESTINY Breast-05 on adjuvant treatment for high-risk residual disease• HER2CLIMB-05 trial findings and implications for metastatic disease• The role of T-DXd with pertuzumab in frontline settings• The PATINA trial and its significance for triple-positive metastatic breast cancer
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, recent approvals, and conference highlights!
#SABCS2025 #HER2positive #DestinyTrials #OncologyBrothers #BreastCancer

Triple Negative Breast Cancer SABCS 2025 Highlights: Dr. Rebecca Shatsky

In this episode of the Oncology Brothers podcast, we were joined by Dr. Rebecca Shatsky, a breast medical oncologist and director of the Inflammatory and Triple Negative Breast Cancer Program at UC San Diego. We dived into the latest findings from the SABCS 2025 conference, focusing on key studies related to triple negative breast cancer (TNBC).
Join us as we discussed:* The RJBC 1501 study, which explored the role of carboplatin in high-risk early-stage TNBC and its impact on disease-free survival.* Insights from the CITRIN study, which questions the carboplatin paradigm and highlights modern treatment approaches.* The TBCRC-056 and OlympiaN trials, investigating the combination of PARP inhibitors and immunotherapy in patients with germline BRCA and PALB2 mutations.
We unpacked the implications of these studies for clinical practice, including the potential benefits and challenges of incorporating carboplatin and novel therapies into treatment regimens.
Tune in for an informative discussion that aims to keep you updated on the evolving landscape of breast cancer treatment!
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights from the world of oncology!
#SABCS2025 #TNBC #PARPinhibitors #BRCAmutation #ChemoFree #OncologyBrothers #BreastCancer #SABCS25